Vol. 4, Issue 2, 2017October 26, 2016 EDT
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally,
1.
Hux M, Zou D, Ma E, et al. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. JHEOR. 2016;4(2):188-203. doi:10.36469/9820